Trial Profile
A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- 25 Jul 2017 Status changed from active, no longer recruiting to discontinued due to low accrual.
- 04 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.